We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genzyme to Acquire Remaining 78% of Focal

By HospiMedica staff writers
Posted on 18 May 2001
In a move that will add intellectual property and expertise with synthetic biomaterials to its biosurgery unit, Genzyme Corp. More...
(Cambridge, MA, USA) has agreed to acquire Focal, Inc. (Lexington, MA, USA) and merge its operations with Genzyme's Biosurgery unit. Genzyme currently owns 22% of Focal and will purchase the remaining 78% in an exchange of stock.

Genzyme Biosurgery will also gain worldwide rights to market FocalSeal-L, a synthetic liquid polymer used to seal air leaks that develop during lung surgery. In addition, the company will acquire a pipeline of biomaterials being developed for other types of surgeries, including FocalSeal-S for use in sealing the dura following brain or spinal surgery. Genzyme Corp. invested US$15 million in Focal in exchange for North American marketing rights to FocalSeal-L.

"Obtaining Focal's extensive intellectual property and promising product pipeline will expand our leadership position in the emerging field of surgical biomaterials,” said Duke Collier, president of Genzyme Biosurgery.




Related Links:
Genzyme

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.